Medical Billers and Coders

Dermatology biologic claims are facing increased denials in 2026 due to stricter payer policies, prior authorization requirements, documentation scrutiny, and evolving reimbursement guidelines. Biologic therapies are high-cost treatments commonly used for psoriasis, eczema, and other chronic dermatologic conditions. Because of their expense and long-term use, payers are applying tighter review processes, leading to more frequent claim denials and payment delays . Understanding these trends is essential for protecting revenue in dermatology practices. What Is Driving Higher Denials for Dermatology Biologic Claims? Several factors are contributing to rising dermatology biologic claim denials in 2026. Key drivers include: Stricter prior authorization policies Step therapy enforcement Limited formulary coverage Increased medical necessity documentation requirements Frequent policy updates by commercial payers Failure to meet any of these requirements often results...